Literature DB >> 19188548

Failure of medical therapy in pulmonary arterial hypertension. Is there an alternative diagnosis?

Susan Harch1, Helen Whitford2, Catriona McLean3.   

Abstract

BACKGROUND: Despite the development of targeted therapies for pulmonary arterial hypertension (PAH), some patients fail to respond to medical therapy. There are a number of types of PAH, one of which is pulmonary venoocclusive disease (PVOD). Unlike other PAH types, the hallmark pathology of PVOD is fibrous occlusion of the small venules, potentially with arterial involvement. It was hypothesized that a lack of response to medical therapy in clinically diagnosed PAH can be explained by misdiagnosed PVOD.
METHODS: This study reviewed cases of 14 patients with clinically diagnosed PAH who had failed to respond to medical therapy and had lung tissue available from autopsy or explant. Control samples (n = 6) were obtained from lungs explanted for other causes, and a previous transthoracic echocardiogram excluded pulmonary hypertension. Comprehensive vessel morphometry was performed, and the clinical data reviewed.
RESULTS: Vessel analysis confirmed 86% of case patients had PVOD and 14% had arterial-only PAH (artPAH). In the PVOD case patients, significant pathology was present in all vessel types with similar obstructive, intimal fibrosis in the venules (p < 0.0001) and arterioles (p < 0.0001). This was considerably different from the intimal concentric laminar smooth muscle proliferation in the artPAH cases. There were no significant differences in clinical presentation between PVOD and artPAH case patients. Pulmonary edema was not observed in the PVOD cases.
CONCLUSIONS: PVOD is an underdiagnosed and commonly misdiagnosed cause of pulmonary hypertension, which may present with a failure to respond to medical therapy. Further studies on PVOD may help confirm whether a change in its classification as a type of PAH is necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188548     DOI: 10.1378/chest.08-2006

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Pulmonary veno-occlusive disease: a misnomer?

Authors:  Cindy R Miller
Journal:  Pediatr Radiol       Date:  2012-02-05

2.  Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Nicole B Gabler; Benjamin French; Brian L Strom; Ziyue Liu; Harold I Palevsky; Darren B Taichman; Steven M Kawut; Scott D Halpern
Journal:  Chest       Date:  2011-09-22       Impact factor: 9.410

3.  Pulmonary arterial remodeling in chronic obstructive pulmonary disease is lobe dependent.

Authors:  Jeremy P Wrobel; Catriona A McLean; Bruce R Thompson; Christopher R Stuart-Andrews; Eldho Paul; Gregory I Snell; Trevor J Williams
Journal:  Pulm Circ       Date:  2013-12-11       Impact factor: 3.017

4.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

5.  Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.

Authors:  Nauman A Khan; Rizwan A Khan; Adriano R Tonelli; Kristin B Highland; Neal F Chaisson; Miriam Jacob; Rahul Renapurkar; Raed A Dweik; Gustavo A Heresi
Journal:  Chest       Date:  2019-02-15       Impact factor: 9.410

6.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

7.  Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Authors:  Jan K Hennigs; Gunhild Keller; Hans Jörg Baumann; Friedemann Honecker; Stefan Kluge; Carsten Bokemeyer; Tim H Brümmendorf; Hans Klose
Journal:  BMC Pulm Med       Date:  2011-05-23       Impact factor: 3.317

8.  Pulmonary hypertension secondary to pulmonary veno-occlusive disease complicated by right heart failure, hypotension and acute kidney injury.

Authors:  Nima Golzy; Stuti Fernandes; Justin Sharim; Rikin Tank; Henry D Tazelaar; Howard E Epstein; Victor Tapson; Antoine Hage
Journal:  Respir Med Case Rep       Date:  2016-09-27

9.  Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension.

Authors:  Said Hajouli; Muhamad Alhaj Moustafa; Jessica S Wang Memoli
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

10.  In search of markers of treatment failure and poor prognosis in IPAH - the value of mosaic lung attenuation pattern on thin-section CT scans.

Authors:  Monika Szturmowicz; Aneta Kacprzak; Barbara Burakowska; Marcin Kurzyna; Anna Fijałkowska; Iwona Bestry; Adam Torbicki
Journal:  Multidiscip Respir Med       Date:  2010-12-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.